Zynteglo is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Bluebird Bio, Inc.. The primary component is Betibeglogene Autotemcel.
Product ID | 73554-3111_f45a90ae-d8b0-43ce-a560-b906e33c9e23 |
NDC | 73554-3111 |
Product Type | Cellular Therapy |
Proprietary Name | Zynteglo |
Generic Name | Betibeglogene Autotemcel |
Dosage Form | Suspension |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2022-08-17 |
Marketing Category | BLA / |
Application Number | BLA125717 |
Labeler Name | bluebird bio, Inc. |
Substance Name | BETIBEGLOGENE AUTOTEMCEL |
Active Ingredient Strength | 20000000 1/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-08-17 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ZYNTEGLO 98405200 not registered Live/Pending |
bluebird bio, Inc. 2024-02-14 |
ZYNTEGLO 98405197 not registered Live/Pending |
bluebird bio, Inc. 2024-02-14 |
ZYNTEGLO 98405188 not registered Live/Pending |
bluebird bio, Inc. 2024-02-14 |
ZYNTEGLO 97132197 not registered Live/Pending |
bluebird bio, Inc. 2021-11-18 |
ZYNTEGLO 79271989 not registered Live/Pending |
Bluebird Bio (UK) Ltd. 2019-10-10 |
ZYNTEGLO 79254523 5887775 Live/Registered |
bluebird bio, Inc. 2019-01-30 |